Telo Genomics Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Allen Farlinger
- Full Time Employees
- 8
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 555 Richmond Street West Toronto ON Canada M5V 3B1
- IPO Date
- Feb 15, 2012
- Website
- telodx.com
- Similar Companies
- Business
- Telo Genomics Corp. is a biotechnology firm specializing in the creation and delivery of advanced diagnostic and prognostic tools designed to tailor treatment strategies for individuals facing particular health challenges. The company leverages a unique telomere analysis platform, integrating quantitative 3D telomere analysis with molecular biology and artificial intelligence, to assess genomic instability. This approach enables predictive and prognostic applications across oncology and neurological disorders. Central to their offerings is the TeloView software platform, which precisely quantifies specific characteristics of each patient’s telomeres to provide insights into disease aggressiveness, risk, and optimal therapeutic responses. Their primary focus, Telo-MM, aims to equip medical professionals with crucial, actionable data for managing Multiple Myeloma, a severe form of blood cancer. Key products include TeloViewSMM, designed to predict the progression of smoldering multiple myeloma, and TeloViewNDMM, which forecasts relapse in newly diagnosed multiple myeloma patients. They are also developing solutions for minimal residual disease (MRD) monitoring, identifying residual cancer cells after treatment. Telo Genomics actively collaborates with prominent institutions, including an expanded partnership with the Mayo Clinic, to validate its Telo-MM tests for multiple myeloma, with recent validation of TeloViewSMM and ongoing validation for TeloViewNDMM. Their technology’s effectiveness has been supported by over 160 peer-reviewed publications and 30 clinical studies involving more than 3,000 patients across various cancers and Alzheimer’s disease. The company serves a diverse market, including pathologists, clinicians, academic researchers, and drug developers. Telo Genomics, formerly known as 3D Signatures Inc. until its name change in April 2019, was established in 2011 and operates from its headquarters in Toronto, Canada, recently relocating its clinical laboratories to a larger, state-of-the-art facility in the Greater Toronto Area to support expanding operations. In late 2024, the company successfully closed an oversubscribed private placement, raising $2.5 million to advance its commercialization plans and product development pipeline, including initiatives in prostate cancer.
Company News
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse
Telo Genomics Grants Stock Options
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment
Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma
Telo Genomics Announces Termination of Investor Relations Agreement
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman
Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing
Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement
Telo Genomics Closes First Tranche of Convertible Debentures Financing
Telo Genomics Announces Appointment of John Price as Chief Financial Officer
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program
Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting
Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th
Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025
American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition
Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update
Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting